Tyler Rehbein,Tong Tong Wu,Simona Treidler,Davide Pareyson,Richard Lewis,Sabrina W Yum,Brett A McCray,Sindhu Ramchandren,Joshua Burns,Jun Li,Richard S Finkel,Steven S Scherer,Stephan Zuchner,Michael E Shy,Mary M Reilly,David N Herrmann,Julian Blake,Kayla Cornett,Thomas O Crawford,Federica Rachele Danti,Gabrielle Donlevy,Katy Eichinger,Tim Estilow,Shawna M E Feely,Matilde Laura,Manoj Menezes,Isabella Moroni,Chiara Pisciotta,Alex Rossor,Gita Ramdharry,Paola Saveri,Giulia Schirinzi,Rosemary R Shy,Mariola Skorupinska,Janet E Sowden,Charlotte J Sumner,Dragan Vujovic,Inherited Neuropathy Consortium-Rare Diseases Clinical Research Network (INC-RDCRN)

Abstract:Recessive SH3TC2 variants cause Charcot-Marie-Tooth disease type 4C (CMT4C). CMT4C is typically a sensorimotor demyelinating polyneuropathy, marked by early onset spinal deformities, but its clinical characteristics and severity are quite variable. Clear relationships between pathogenic variants and the spectrum of disease manifestations are to date lacking. Gene replacement therapy has been shown to ameliorate the phenotype in a mouse model of CMT4C, emphasizing the need for natural history studies to inform clinical trial readiness. Data, including both genetic information and clinical characteristics, were compiled from the longitudinal, prospective dataset of the Inherited Neuropathy Consortium, a member of the Rare Diseases Clinical Research Network (INC-RDCRN). The Charcot Marie Tooth Neuropathy Score (CMTNS), Examination Score (CMTES) and the Rasch-weighted CMTES (CMTES-R) were used to describe symptoms, neurologic examinations, and neurophysiologic characteristics. Standardized response means were calculated at yearly intervals and a mixed model for repeated measures was used to estimate the change in CMTES and CMTES-R over time. 56 individuals (59% female), median age 27 years (range 2–67 years) with homozygous or compound heterozygous variants in SH3TC2 were identified, including 34 unique variants, 14 of which have not previously been published. 28 participants had longitudinal data available. While there was not a significant difference in the CMTES in those with protein-truncating versus non-protein-truncating variants, there were significant differences in the mean ulnar nerve compound muscle action potential amplitude, the mean radial sensory nerve action potential amplitude, and in the prevalence of scoliosis, suggesting the possibility of a milder phenotype in individuals with one or two non-protein-truncating variants. Overall, the mean value of the CMTES was 13, reflecting moderate clinical severity. There was a high rate of scoliosis (81%), scoliosis surgery (36%), and walking difficulty (94%) among study participants. The CMTES and CMTES-R appeared moderately responsive to change over extended follow-up, demonstrating a standardized response mean of 0.81 standard deviation units or 0.71 standard deviation units respectively, over 3 years. Our analysis represents the largest cross-sectional and only longitudinal study to date, of the clinical phenotype of both adults and children with CMT4C. With the promise of upcoming genetic treatments, this data will further define the natural history of the disease and inform study design in preparation for clinical trials.

Demyelination in hereditary sensory neuropathy type‐1C

Functional and Molecular Characterization of New SPTLC1 Missense Variants in Patients with Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1)

SPTAN1 Variants Likely Cause Autosomal Recessive Complicated Hereditary Spastic Paraplegia

Calcium-Mediated Calpain Activation and Microtubule Dissociation in Cell Model of Hereditary Sensory Neuropathy Type-1 Expressing V144D SPTLC1 Mutation

Compound Heterozygous Mutations in the Neuraminidase 1 Gene in Type 1 Sialidosis: A Case Report and Review of Literature

Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis

Molecular Myelin Dysfunction in the Most Common Inherited Peripheral Neuropathies - CMT1A and HNPP

Specific Deoxyceramide Species Correlate with Expression of Macular Telangiectasia Type 2 (MacTel2) in a SPTLC2 Carrier HSAN1 Family

ATL3 gene mutation in a Chinese family with hereditary sensory neuropathy type 1F

Hereditary sensory neuropathy type I

Recurrent de-novo gain-of-function mutation in SPTLC2 confirms dysregulated sphingolipid production to cause juvenile amyotrophic lateral sclerosis

Lack of SPNS1 results in accumulation of lysolipids and lysosomal storage disease in mouse models

Loss of SPNS1, a lysosomal transporter, in the nervous system causes dysmyelination and white matter dysplasia

Biallelic mutations in sord are a common cause of potentially treatable genetic neuropathy

Clinical electrophysiological and pathological study on hereditary sensory and autonomic neuropathy type I in a Chinese family

Severe central nervous system demyelination in Sanfilippo disease

A de novo c.113 T > C: p.L38R mutation of SPTLC1: case report of a girl with sporadic juvenile amyotrophic lateral sclerosis

1-Deoxysphingolipids cause autophagosome and lysosome accumulation and trigger NLRP3 inflammasome activation

Mutations in the nervous system--specific HSN2 exon of WNK1 cause hereditary sensory neuropathy type II

Neuropathy due to bi-allelic SH3TC2 variants: Genotype-phenotype correlation and natural history

Neutral Lipid Storage Disease with Myopathy: a Family Report